Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.

Item request has been placed!

Item request cannot be made.

Processing Request

Read Online Read More Add to Saved list

Author(s): Wang, De-Shen¹ (AUTHOR); Ren, Chao¹ (AUTHOR); Li, Shan-Shan² (AUTHOR); Fong, William Pat¹ (AUTHOR); Wu, Xiao-Jun³ (AUTHOR); Xiao, Jian^2,4 (AUTHOR); Li, Bin-Kui⁵ (AUTHOR); Zheng, Yun⁵ (AUTHOR); Ding, Pei-Rong³ (AUTHOR); Chen, Gong³ (AUTHOR); Qiu, Miao-Zhen¹ (AUTHOR); Wang, Zhi-Qiang¹ (AUTHOR); Wang, Feng-Hua¹ (AUTHOR); Luo, Hui-Yan¹ (AUTHOR); Wang, Feng¹ (AUTHOR); Wang, Xiao-Zhong⁶ (AUTHOR); Wang, Ling-Yun⁷ (AUTHOR); Xie, De-Jin⁶ (AUTHOR); Chen, Tao⁷ (AUTHOR); Li, Li-Ren³ (AUTHOR)
Source:
PLoS Medicine. 5/10/2024, Vol. 21 Issue 5, p1-18. 18p.